SCHEMBL14770501

SCHEMBL14770501

Cc1ccc(C(C)c2nc3cc(F)ccc3[nH]2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLKL Q8NB16 3/20 0.46
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43
CYP1A2 P05177 1/20 0.42
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.40
KIF11 P52732 1/20 0.38
LMNA P02545 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NPSR1 Q6W5P4 1/20 0.37
BRD4 O60885 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770492 0.85 AMY1A (0.41) ALPLALPIALPGALDH1A1HPGD
SCHEMBL14770477 0.84 MLKL (0.66) MLKLALPLALPIALPGCYP1A2
SCHEMBL14770563 0.83 BRD4 (0.41) ALPLALPIALPGALDH1A1BRD4
SCHEMBL29212574 0.82 KDM4E (0.51) MLKLALPLALPIALPGCYP1A2
SCHEMBL14770508 0.82 KMT2A (0.49) ALPLALPIALPGALDH1A1HPGD
SCHEMBL14770660 0.80 MLKL (0.42) MLKLCYP1A2ALDH1A1HPGDUSP2
SCHEMBL4111095 0.80 HSD17B10 (0.57) MLKLALPLALPIALPGCYP1A2
SCHEMBL14770504 0.79 BRD4 (0.42) ALPLALPIALPGBRD4
SCHEMBL14770537 0.79 CACNA1C (0.38) MLKLCYP1A2ALDH1A1HPGDHTT
SCHEMBL14770503 0.77 AMY1A (0.42) ALPLALPIALPGBRD4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A MLKL 2378/4885ALPL 4272/4885ALPI 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.